國立虎尾科技大學 |

Cancer Immunotherapies = Solid Tumors and Hematologic Malignancies /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Cancer Immunotherapies/ edited by Priya Hays.
其他題名:	Solid Tumors and Hematologic Malignancies /
其他作者:	Hays, Priya.
面頁冊數:	XVI, 315 p. 32 illus., 31 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Genomics. -
電子資源:	https://doi.org/10.1007/978-3-030-96376-7
ISBN:	9783030963767

Cancer Immunotherapies = Solid Tumors and Hematologic Malignancies /
Cancer ImmunotherapiesSolid Tumors and Hematologic Malignancies /[electronic resource] :edited by Priya Hays. - 1st ed. 2022. - XVI, 315 p. 32 illus., 31 illus. in color.online resource. - Cancer Treatment and Research,1832509-8497 ;. - Cancer Treatment and Research,165.

Development of Cancer Immunotherapies -- Melanoma -- Engaging pattern recognition receptors in solid tumors to generate systemic anti-tumor immunity -- Allogeneic tumor antigen-specific T cells for broadly applicable adoptive cell therapy of cancer -- Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma -- Lag3: From Bench to Bedside -- Immunotherapy in Genitourinary Malignancy: evolution in revolution or revolution in evolution -- Immune-based therapeutic interventions for Acute Myeloid Leukemia.-Off-the-shelf chimeric antigen receptor immune cells from human pluripotent stem cells -- The single-cell level perspective of the tumor microenvironment and its remodeling by CAR-T cells -- Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematological Malignancies.

This book presents the clinical scope of cancer immunotherapeutic agents for solid tumors and Hematologic malignancies, elaborates on the scientific details of their modes of action, and presents the impact of these agents on oncology, patients and the broader healthcare system. At present, cancer immunotherapies fall broadly into three categories: immune checkpoint inhibitors (ICIs), adoptive T cell therapies, and cancer vaccines which have distinct mechanisms of action. Immune checkpoint inhibitors rely upon disrupting tumor antigen recognition as self by the immune system through inhibition of checkpoint molecules. Adoptive T cell therapies involve the engineering of T cells ex vivo to target and destroy tumor cells. The first part of this book will provide an overview of the discovery and mechanistic details of the technology. The second part will be devoted to elaborating on the clinical outcomes, successes and limitations for specific tumor subtypes, which includes both solid tumors and hematologic malignances for both pediatric and adult populations. As such, the book offers a valuable resource for oncologists, hematologists, and all those seeking an up-to-date overview of cancer immunotherapies.

ISBN: 9783030963767

Standard No.: 10.1007/978-3-030-96376-7doiSubjects--Topical Terms:

578973
Genomics.

LC Class. No.: RC254-282

Dewey Class. No.: 616.994

Cancer Immunotherapies = Solid Tumors and Hematologic Malignancies /
LDR:03443nam a22004095i 4500 001 1087048
003 DE-He213
005 20220512102423.0
007 cr nn 008mamaa
008 221228s2022 sz | s |||| 0|eng d
020 $a 9783030963767 $9 978-3-030-96376-7
024 7 $a 10.1007/978-3-030-96376-7 $2 doi
035 $a 978-3-030-96376-7
050 4 $a RC254-282
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.994 $2 23
245 1 0 $a Cancer Immunotherapies $h [electronic resource] : $b Solid Tumors and Hematologic Malignancies / $c edited by Priya Hays.
250 $a 1st ed. 2022.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2022.
300 $a XVI, 315 p. 32 illus., 31 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Cancer Treatment and Research, $x 2509-8497 ; $v 183
505 0 $a Development of Cancer Immunotherapies -- Melanoma -- Engaging pattern recognition receptors in solid tumors to generate systemic anti-tumor immunity -- Allogeneic tumor antigen-specific T cells for broadly applicable adoptive cell therapy of cancer -- Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma -- Lag3: From Bench to Bedside -- Immunotherapy in Genitourinary Malignancy: evolution in revolution or revolution in evolution -- Immune-based therapeutic interventions for Acute Myeloid Leukemia.-Off-the-shelf chimeric antigen receptor immune cells from human pluripotent stem cells -- The single-cell level perspective of the tumor microenvironment and its remodeling by CAR-T cells -- Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematological Malignancies.
520 $a This book presents the clinical scope of cancer immunotherapeutic agents for solid tumors and Hematologic malignancies, elaborates on the scientific details of their modes of action, and presents the impact of these agents on oncology, patients and the broader healthcare system. At present, cancer immunotherapies fall broadly into three categories: immune checkpoint inhibitors (ICIs), adoptive T cell therapies, and cancer vaccines which have distinct mechanisms of action. Immune checkpoint inhibitors rely upon disrupting tumor antigen recognition as self by the immune system through inhibition of checkpoint molecules. Adoptive T cell therapies involve the engineering of T cells ex vivo to target and destroy tumor cells. The first part of this book will provide an overview of the discovery and mechanistic details of the technology. The second part will be devoted to elaborating on the clinical outcomes, successes and limitations for specific tumor subtypes, which includes both solid tumors and hematologic malignances for both pediatric and adult populations. As such, the book offers a valuable resource for oncologists, hematologists, and all those seeking an up-to-date overview of cancer immunotherapies.
650 0 $a Genomics. $3 578973
650 0 $a Genetics. $3 578972
650 0 $a Hematology. $3 645254
650 0 $a Oncology. $3 593951
700 1 $a Hays, Priya. $e author. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1357158
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030963750
776 0 8 $i Printed edition: $z 9783030963774
776 0 8 $i Printed edition: $z 9783030963781
830 0 $a Cancer Treatment and Research, $x 0927-3042 ; $v 165 $3 1254896
856 4 0 $u https://doi.org/10.1007/978-3-030-96376-7
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)